John Wobel's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q4 2024
Question
An analyst on behalf of John Wobel asked for the regulatory and commercial rationale behind using a novel, differentiated endpoint for the atumelnant Phase III CAH trial.
Answer
CEO R. Struthers explained that atumelnant's unique mechanism aims to make it the primary treatment for CAH, with glucocorticoids used only for replacement. Chief Medical and Development Officer Dana Pizzuti added that the proposed endpoint will capture both dimensions of the drug's effect—reducing androgens and allowing for lower glucocorticoid doses—which could support a differentiated indication.